GlaxoWellcome Signs License Agreement for Advanced Chemistry Development's NMR Data
Processing, Management and Prediction Software
|
|
TORONTO - March 23,1999 -
Advanced Chemistry Development and GlaxoWellcome, Research Triangle Park, have reached an agreement which provides GlaxoWellcome with the use of Advanced Chemistry's experimental data processing and management software. Under the agreement GlaxoWellcome chemists will have full use of all state-of-the-art ACD/NMR software packages:
- ACD/NMR Manager
- ACD/HNMR and ACD/CNMR Predictors
- ACD/2D Processor
- ACD/Structure Elucidator
- ACD/Combi NMR
"ACD has been providing software to GlaxoWellcome chemists since
1994," said Antony WIlliams, Chief Science Officer at Advanced Chemistry Development.
"This agreement is an indication of our commitment to provide tools that can be
utilized across corporations to enable spectral data process and management at the
desktop. We are happy that GlaxoWellcome has chosen to take advantage of these
capabilities"
GlaxoWellcome, plc (www.glaxowellcome.com)
is an international pharmaceutical company committed to fighting disease by bringing
innovative medicines and services to patients and to the healthcare providers who serve
them. The company's prescription medication line in the United States includes more
than 60 products. GlaxoWellcome currently employs approximately 54,000 employees
worldwide.
Advanced Chemistry Development Inc. is a leader in the field of
physical property prediction, desktop spectroscopy management, systematic naming, and
Web-based access to chemistry prediction. Founded in 1993 and with headquarters in
Toronto, Canada, the company employs over 90 people and has established worldwide
distribution channels. ACD Labs' mission is to define a new standard in capability for
Chemistry based software addressing the needs of spectroscopy, physical property
prediction, and systematic naming.
|
